Launch of IND-Enabling studies for IPH4102

• IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor specifically expressed by some rare forms of cancer
• It is developed in an orphan disease, cutaneous T-cell lymphomas, and especially their aggressive forms: Sezary Syndrome and Transformed Mycosis Fungoides
• An investigational new drug (IND) application should be submitted in late 2014
• Innate Pharma intends to develop IPH4102 as a proprietary program

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announced today that it had selected and qualified the IPH4102 drug candidate for further development.

IPH4102 is a first-in-class cytotoxic antibody developed in some types of KIR3DL2-expressing cancers, such as the Sezary Syndrome (“SS”) and Transformed Mycosis Fungoides (“TMF”), which are aggressive forms of cutaneous T-cell lymphomas. IND-enabling studies and industrial production of the molecule have begun. The IND application is expected to be submitted in late 2014.